Phytomedicine : international journal of phytotherapy and phytopharmacology · 2025
Lycorine suppresses hepatocellular carcinoma via the reprogramming of myeloid and epithelial cells.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gu Xinyu, Ma Fuqiang, Liu Yafeng, Zhang Shujun, Chen Wenjuan, Zhang Lifan, Zhang Lele, Lu Juan, Hu Xinjun
Аннотация
BACKGROUND: Hepatocellular carcinoma (HCC) is an aggressive malignancy associated with an immunosuppressive tumor microenvironment (TME), which contributes to resistance to therapy. Lycorine, a natural alkaloid, has demonstrated anticancer potential, but its effects on HCC remain insufficiently explored.
PURPOSE: This study aimed to systematically assess the impact of lycorine on HCC and elucidate its underlying mechanisms of action.
STUDY DESIGN: In vivo orthotopic HCC mouse models were employed, incorporating high-dimensional single-cell techniques to comprehensively analyze the effects of lycorine on the TME.
METHODS: Mice bearing orthotopic HCC tumors were treated with lycorine at doses of 10 or 20 mg/kg for 14 days. Tumor progression was assessed by measuring tumor weight. The immune landscape was examined using cytometry by time of flight (CyTOF), and cellular heterogeneity was evaluated via single-cell RNA sequencing (scRNA-seq). Cell-cell communication networks were reconstructed through CellChat analysis.
RESULTS: Lycorine treatment significantly reduced tumor burden and modulated cytokine expression profiles. CyTOF analysis revealed that lycorine reprogrammed the immune landscape, enhancing macrophage and neutrophil infiltration while decreasing PD-L1 expression on neutrophils. scRNA-seq analysis indicated that lycorine regulated specific cell subpopulations, including malignant epithelial cells, Notch2+ neutrophils, and Spp1+ macrophages. Cell-cell communication analysis identified the regulation of the Mif-(Cd74+Cd44/Cxcr4) signaling axis as a key underlying mechanism.
CONCLUSION: Lycorine remodels the HCC TME through coordinated actions on malignant epithelial cells and immune populations, notably neutrophil and macrophage subpopulations. These findings support the potential development of lycorine-based combination therapies for HCC.
PURPOSE: This study aimed to systematically assess the impact of lycorine on HCC and elucidate its underlying mechanisms of action.
STUDY DESIGN: In vivo orthotopic HCC mouse models were employed, incorporating high-dimensional single-cell techniques to comprehensively analyze the effects of lycorine on the TME.
METHODS: Mice bearing orthotopic HCC tumors were treated with lycorine at doses of 10 or 20 mg/kg for 14 days. Tumor progression was assessed by measuring tumor weight. The immune landscape was examined using cytometry by time of flight (CyTOF), and cellular heterogeneity was evaluated via single-cell RNA sequencing (scRNA-seq). Cell-cell communication networks were reconstructed through CellChat analysis.
RESULTS: Lycorine treatment significantly reduced tumor burden and modulated cytokine expression profiles. CyTOF analysis revealed that lycorine reprogrammed the immune landscape, enhancing macrophage and neutrophil infiltration while decreasing PD-L1 expression on neutrophils. scRNA-seq analysis indicated that lycorine regulated specific cell subpopulations, including malignant epithelial cells, Notch2+ neutrophils, and Spp1+ macrophages. Cell-cell communication analysis identified the regulation of the Mif-(Cd74+Cd44/Cxcr4) signaling axis as a key underlying mechanism.
CONCLUSION: Lycorine remodels the HCC TME through coordinated actions on malignant epithelial cells and immune populations, notably neutrophil and macrophage subpopulations. These findings support the potential development of lycorine-based combination therapies for HCC.